SEC For	m 4																
	FORM	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See						NT OF CHANGES IN BENEFICIAL OWNERS								OMB Number:     3235-0287       Estimated average burden     hours per response:     0.5			
1. Name and Address of Reporting Person* Fair Richard A. (Last) (First) (Middle) C/O BELLICUM PHARMACEUTICALS, IN 3730 KIRBY DRIVE, SUITE 1200				E									ationship of Reporting Person(s) to Issuer (all applicable) Director 10% Owner Officer (give title Other (specify below) below) President and CEO				
(Street) HOUST(	ON T	77098	4	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City) (State) (Zip)												<u> </u>					
Table I - Non-Deriv.   1. Title of Security (Instr. 3)   2. Transa Date (Month/L)					ction 2A. Deemed Execution Date,		3. Transact Code (In	ion Dispose	ities Acquir d Of (D) (Ins	ed (A) or str. 3, 4 and s	5. Amount of		Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Table II - De (e.					uired, Dis s, options				Owned	-	1	I		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title an of Securit Underlyin Derivative (Instr. 3 ar	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	1011(3)			
Stock Option (right to buy)	\$2.91	08/16/2021		A		265,000		(1)	08/16/2031	Common Stock	265,000	\$0	265,0	00	D		

## Explanation of Responses:

1. 50% of the shares subject to the stock option vest and become exercisable on December 15, 2021, and the remaining shares subject to the stock option vest and become exercisable in 12 equal monthly installments thereafter.

**Remarks:** 

/s/ Richard A. Fair

08/16/2021 Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.